Clinical Trials

Find trials

Perform a New Search

Search Results 51-60 of 70 for Metastatic colorectal cancer

Edit search filters

A Study To Evaluate Trifluridine/Tipiracil Combined With Bevacizumab Vs Trifluridine/Tipiracil To Treat Patients With Refractory Metastatic Colorectal Cancer

Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

See Details

A Study To Evaluate Trifluridine/Tipiracil Combined With Bevacizumab Vs Trifluridine/Tipiracil To Treat Patients With Refractory Metastatic Colorectal Cancer

Study type:
Interventional
Describes the nature of a clinical study. Types include:
- Observational study — observes people and measures outcomes without affecting results.
- Interventional study (clinical trial) — studies new tests, treatments, drugs, surgical procedures or devices.
- Medical records research — uses historical information collected from medical records of large groups of people to study how diseases progress and which treatments and surgeries work best.
Study phase:
3
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

About this study

The purpose of this study is to evaluate the effectiveness and safety of trifluridine/tipiracil in combination with bevacizumab versus trifluridine/tipiracil monotherapy in patients with refractory metastatic colorectal cancer (mCRC).

Participating Mayo Clinic locations

Study statuses change often. Please contact us for help.

Mayo Clinic Location	Status	Contact
Scottsdale/Phoenix, AZ	Closed for enrollment	View complete study & contact information
Jacksonville, FL	Closed for enrollment
Rochester, MN	Closed for enrollment

Print study details

Site IRB:
21-005096
NCT ID:
NCT04737187
Sponsor Protocol Number:
CL3-95005-007

A Study To Evaluate Regorafenib With Cetuximab Or Panitumumab To Treat Unresectable, Locally Advanced, Or Metastatic Colorectal Cancer

Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

See Details

A Study To Evaluate Regorafenib With Cetuximab Or Panitumumab To Treat Unresectable, Locally Advanced, Or Metastatic Colorectal Cancer

Study type:
Interventional
Describes the nature of a clinical study. Types include:
- Observational study — observes people and measures outcomes without affecting results.
- Interventional study (clinical trial) — studies new tests, treatments, drugs, surgical procedures or devices.
- Medical records research — uses historical information collected from medical records of large groups of people to study how diseases progress and which treatments and surgeries work best.
Study phase:
2
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

About this study

The purpose of this study is to determine how well regorafenib and anti-EGFR therapy (cetuximab or panitumumab) works for the treatment of patients with colorectal cancer that cannot be removed by surgery (unresectable), has spread to nearby tissue or lymph nodes (locally advanced), or has spread to other places in the body (metastatic). Regorafenib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as cetuximab or panitumumab, may interfere with the ability of cancer cells to grow and spread. Drugs used in chemotherapy, such as irinotecan, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. The purpose of this research study is to compare the effects, good and/or bad, of taking regorafenib follow by cetuximab or panitumumab, to those that receive cetuximab or panitumumab before regorafenib.

Participating Mayo Clinic locations

Study statuses change often. Please contact us for help.

Mayo Clinic Location	Status	Contact
Scottsdale/Phoenix, AZ	Closed for enrollment	View complete study & contact information
Jacksonville, FL	Closed for enrollment
Rochester, MN	Closed for enrollment

Print study details

Site IRB:
20-000071
NCT ID:
NCT04117945
Sponsor Protocol Number:
ACCRU-GI-1809

Mayo Clinic Location	Status	Contact
Rochester, MN	Closed for enrollment	View complete study & contact information

Durvalumab And Tremelimumab With Or Without High Or Low-Dose Radiation Therapy In Treating Patients With Metastatic Colorectal Or Non-small Cell Lung Cancer

Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

See Details

Durvalumab And Tremelimumab With Or Without High Or Low-Dose Radiation Therapy In Treating Patients With Metastatic Colorectal Or Non-small Cell Lung Cancer

Study type:
Interventional
Describes the nature of a clinical study. Types include:
- Observational study — observes people and measures outcomes without affecting results.
- Interventional study (clinical trial) — studies new tests, treatments, drugs, surgical procedures or devices.
- Medical records research — uses historical information collected from medical records of large groups of people to study how diseases progress and which treatments and surgeries work best.
Study phase:
2
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

About this study

This phase II trial studies the side effects of durvalumab and tremelimumab and to see how well they work with or without high or low-dose radiation therapy in treating patients with colorectal or non-small cell lung cancer that has spread to other parts of the body. Monoclonal antibodies, such as durvalumab and tremelimumab, may interfere with the ability of tumor cells to grow and spread. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Giving durvalumab and tremelimumab with radiation therapy may work better in treating patients with colorectal or non-small cell lung cancer.

Participating Mayo Clinic locations

Study statuses change often. Please contact us for help.

Mayo Clinic Location	Status	Contact
Scottsdale/Phoenix, AZ	Closed for enrollment	View complete study & contact information
Jacksonville, FL	Closed for enrollment
Rochester, MN	Closed for enrollment

Print study details

Site IRB:
17-002107
NCT ID:
NCT02888743
Sponsor Protocol Number:
10021

Pagination Clinical studies

Clinical Trials

Filter Results

Locations

Study status

Gender

Age

Study phase

Search Results 51-60 of 70 for Metastatic colorectal cancer

Capecitabine And Bevacizumab With Or Without Atezolizumab In Treating Patients With Refractory Metastatic Colorectal Cancer

Open-label, Single Arm Trial Of BI 695502 In Patients With Previously Untreated Metastatic Colorectal Cancer

Expanded Access Study Of TAS-102 In Patients With Metastatic Colorectal Cancer

Testing The Addition Of Total Ablative Therapy To Usual Systemic Therapy Treatment For Limited Metastatic Colorectal Cancer, The ERASur Study

A Study To Evaluate Trifluridine/Tipiracil Combined With Bevacizumab Vs Trifluridine/Tipiracil To Treat Patients With Refractory Metastatic Colorectal Cancer

A Study To Evaluate Regorafenib With Cetuximab Or Panitumumab To Treat Unresectable, Locally Advanced, Or Metastatic Colorectal Cancer

Study Comparing Veliparib Plus FOLFIRI Versus Placebo Plus FOLFIRI With Or Without Bevacizumab In Previously Untreated Metastatic Colorectal Cancer

Phase II Trial Of Irinotecan, Cetuximab, And Bevacizumab Compared With Irinotecan, Cetuximab, And Placebo In KRAS-Wildtype, Irinotecan-Refractory, Metastatic Colorectal Cancer

Irinotecan And Cetuximab With Or Without Bevacizumab In Treating Patients With RAS Wild-Type Locally Advanced Or Metastatic Colorectal Cancer That Cannot Be Removed By Surgery

Durvalumab And Tremelimumab With Or Without High Or Low-Dose Radiation Therapy In Treating Patients With Metastatic Colorectal Or Non-small Cell Lung Cancer

Mayo Clinic Footer

Legal Conditions and Terms

Advertising

Reprint Permissions